1. <track id="dxadr"><div id="dxadr"><address id="dxadr"></address></div></track>
    <track id="dxadr"></track>
    <bdo id="dxadr"><dfn id="dxadr"><menu id="dxadr"></menu></dfn></bdo>
    <tbody id="dxadr"></tbody>

      INVENTING A NEW
      ROADMAP FOR BIOTECH

      Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.

      Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

      Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite? technologies, such as VelocImmune? which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

      FOR 30 YEARS, OUR
      MISSION HAS BEEN TO
      USE THE POWER OF
      SCIENCE TO BRING
      NEW MEDICINES TO
      PATIENTS... OVER
      AND OVER AGAIN.

      Neil Stahl, PhD, Executive VP,
      Research and Development

      2018 annual report PDF download

      Check out our 2018 annual materials. The Responsibility Report and Annual Report are now online.

      Read our annual report
      and responsibility report

      2018 responsibility report PDF download

      REGENERON BY THE NUMBERS

      • 30
        years of scientific
        leadership
      • 7,300+
        employees
        worldwide
      • 700+
        employees with
        an MD, PhD or
        PharmD degree
      • 6TH
        consecutive year
        in Forbes' World's
        Most Innovative
        Companies
      • #1
        ranking in Science
        magazine’s global Top
        Employer survey for six
        of the past eight years
      • 31,000+
        employee volunteer hours
        for 100+ organizations
        in 2018
      • 7
        FDA-approved
        medicines
      • 94%
        of our waste
        diverted from
        landfill, reaching
        our goal
      • 100%
        of drug candidates
        invented and
        developed in-house
      • 500,000+
        exomes sequenced
        to date
      • 100+
        publications in 2018
      • 20
        product candidates in
        clinical development
        across multiple
        therapeutic areas
      • Shingo Institute: The Shingo Prize, 2019

        Great Places to Work: Best Workplace in Ireland, 2019

        Science: #1 Top Employer, 2018

        Forbes: Top 10 Most Innovative Companies, 2018

        Civic 50: Most Community-Minded Companies in the Nation, 2018

        Fortune: Best Companies to Work for, 2018

      • MIT Technology Review: Top 10 Smartest Companies, 2017

        Fortune: Future 50, 2017

        Barron’s: World’s Best CEOs, 2016

        Scrip Award: R&D Team of the Year, 2016

        Crain’s New York Business: Fast 50, 2015

      LEADERSHIP

      We are the only biopharmaceutical company to be led by physician-scientists for more than 30 years. We consistently demonstrate our commitment to scientific excellence by counting multiple Nobel Laureates and five members of the National Academy of Sciences among our leadership, as well as being one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.

      Our leadership

      A FOCUS
      ON SCIENCE

      From our first days, science has remained our central guiding principle.

      Our journey

      操逼的视频